An official website of the United States government
Login Change: CDAS is now using the NIH Researcher Auth Service (RAS) to manage our existing login options. When logging into CDAS, you will be taken to RAS, where you can select your preferred login provider to access CDAS.
This warning banner provides privacy and security notices consistent with applicable federal laws, directives, and other federal guidance for accessing this Government system, which includes (1) this computer network, (2) all computers connected to this network, and (3) all devices and storage media attached to this network or to a computer on this network.
This system is provided for Government-authorized use only.
Unauthorized or improper use of this system is prohibited and may result in disciplinary action and/or civil and criminal penalties.
Personal use of social media and networking sites on this system is limited as to not interfere with official work duties and is subject to monitoring.
By using this system, you understand and consent to the following:
The Government may monitor, record, and audit your system usage, including usage of personal devices and email systems for official duties or to conduct HHS business. Therefore, you have no reasonable expectation of privacy regarding any communication or data transiting or stored on this system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this system.
Any communication or data transiting or stored on this system may be disclosed or used for any lawful Government purpose.
Browse EPPT > UWI10-16-01R 9cUAB30 in Preventing Cancer in Healthy Volunteers
The following datasets contain the data available for EPPT UWI10-16-01R. The description and documentation for each file is listed below. SAS7bdat and CSV versions of the actual data will be available to CDAS projects approved to use this study's data.
1.
The Enhanced Person dataset contains all information relevant for most analyses. Each record represents one participant and contains updated variable names, formats, and labels. All information coming from non-person-based datasets has been converted into a person-based format.
2.
The Adverse Events dataset contains adverse event information, including onset date, grade of severity, attribution to the study agent, and outcome. This version of the dataset includes updated variable names, formats, and labels.
Raw Datasets
These 17 datasets contain the raw form data received, excluding PII.
17.
The vitals dataset contains participant's vitals at the time of visit.
Trial Summary
This randomized phase I double blinded trial is a series of dose escalation studies that observe the frequency and severity of adverse events caused by escalating dose levels of the drug 9cUAB30 in healthy volunteers. The use of 9cUAB30 is suspected to prevent the growth of cancer. The protocol looks to find the recommended phase II dose of 9cUAB30, based on the maximum tolerated dose (the highest dose level with minimal adverse events) and pharmacokinetic measures from plasma and urine sampling. The study began with the UWI09-8-02 (c2003) protocol, which monitored the use of 20mg and 40mg of 9cUAB30. After a lack of unacceptable toxicity in participants, a second study was conducted (UWI10-16-01R (c2003)) which observed 9cUAB30 in amounts of 40mg, 80mg, and 160mg. After a lack of unacceptable toxicity was observed again, a third and final study (UWI10-16-01R (c2012)) was conducted which monitored participants taking 240mg of 9cUAB30.
The UWI10-16-01R (06/29/2015) trial contains randomized protocols with various treatment levels:
UWI09-8-02 (c2003)
Placebo (2 capsules once daily)
9cUAB30 (2 x 10mg capsules (20mg) once daily)
9cUAB30 (2 x 20mg capsules (40mg) once daily)
UWI10-16-01R (c2003)
Placebo (8 capsules once daily)
9cUAB30 (8 x 5mg capsules (40mg) once daily)
9cUAB30 (8 x 10mg capsules (80mg) once daily)
9cUAB30 (8 x 20mg capsules (160mg) once daily)
UWI10-16-01R (c2012)
Placebo (12 capsules once daily)
9cUAB30 (12 x 20mg capsules (240mg) once daily)
Target Enrollment: 33
Statistical Considerations:
The primary objective is to determine the recommended phase II dose of 9cUAB30. For our purposes, the maximally tolerated dose is defined as the highest dose level with < 25% (2 of 8) of treated participants experiencing a grade 3 toxicity that is possibly, probably or definitely related to study drug. The recommended phase II dose will be based on the MTD. The co-primary objective was to characterize the urine and plasma single dose and steady state pharmacokinetics of 9cUAB30 in normal volunteers. Eligible participants were to be randomized in groups of 10, with 8 participants receiving the appropriate dose level of drug and 2 participants receiving placebo, in a double-blind fashion for 28 days. If there was no dose-limiting toxicity and the difference between the AUCs on Day 1 and Day 36 is within tolerance limits, dose was to be escalated and the group with the subsequent drug dose treated. The groups received the following escalating doses: 20 mg, 40 mg, 80 mg, 160 mg, and 240mg.
The secondary objectives are to correlate the pharmacokinetics of 9cUAB30 with toxicity, to compare toxicity between placebo and controls at each dose level, and to assess changes in single dose pharmacokinetics from Day 1 to Day 36.
Enrollment Statistics
Total Enrollment: 54 Participants(35 Female, 19 Male)
1 participant did not complete study due to concomitant medication usage
9cUAB30 240 mg: 8 Participants
6 participants completed study
2 participants did not complete study
1 due to an adverse event
1 due to inability to complete visit 6
9cUAB30 80 mg: 8 Participants
8 participants completed study
9cUAB30 160 mg: 6 Participants
5 participants completed study
2 participants did not complete study
1 ineligible to continue
1 due to an adverse event
Total Study Population Demographics: (53 Randomized and Eligible People)
Sex:
Female: 34 (64%)
Male: 19 (36%)
Race:
White: 46(87%)
Black or African American: 7(13%)
Age (years):
Mean: 42.8
Standard Deviation: ±14
Weight (kg):
Mean: 83.7
Standard Deviation: ±18
BMI (kg/m2):
Mean: 28.9
Standard Deviation: ±6.4
Blood Pressure (mmHg):
Systolic:
Mean: 121
Standard Deviation: ±13
Diastolic:
Mean: 74.7
Standard Deviation: ±8.7
Final Analysis Population: 53
Eligibility Criteria
Inclusion Criteria
Normal volunteers, either male or female
Eastern Cooperative Oncology Group (ECOG) performance status =< 1 or Karnofsky >= 70%
White blood cell (WBC) >= 3000/mm^3
Platelets >= 100,000/mm^3
Hemoglobin > 10 g/dL
Bilirubin =< upper limit of institutional normal
Aspartate aminotransferase (AST) =< upper limit of institutional normal
Creatinine within institutional normal limits
Sodium, potassium, chloride, bicarbonate: all =< upper limit of institutional normal
Fasting triglycerides =< 1.5 x upper limit of normal (ULN)
Fasting cholesterol =< 1.5 x ULN
Participants must agree to discontinue all vitamin supplements while taking study medication and for thirty days past the last dose of study medication
Heterosexual women and men must agree to use TWO effective forms of birth control for the duration of study participation and for 30 days following the last dose of study medication
Men must agree not to donate sperm during the study and for three months after receiving the last dose of study drug
The following persons are not considered to be able to father or bear children and therefore are eligible to participate without the use of concurrent birth control:
Female with bilateral oophorectomy and/or hysterectomy
Female with fallopian tubes cut, tied, or sealed
Female with sterilization implant (e.g. Adiana, Essure) placed > 3 months prior to randomization
Female post-menopausal (> 1 year since last menses)
Male with vasectomy > 3 months prior to randomization
One of the following methods of birth control must be used by women of childbearing potential:
Combined oral contraceptive pill in continuous use for > 30 days prior to study entry
Vaginal ring (e.g. NuvaRing) in continuous use for > 30 days prior to study entry
Skin patch (e.g. Ortho Evra) in continuous use for > 30 days prior to study entry
Injection (e.g. Depo-Provera, Noristerat) in continuous use for > 30 days prior to study entry
Copper intrauterine device (IUD) (e.g. ParaGard)
Note: The following hormonal methods are NOT acceptable:
Low dose progesterone only oral contraceptive pill ("mini pills" e.g. Micronor, Nor-Q.D., Ovrette)
Norplant subdermal implant
Mirena Hormonal Implanted Uterine Device (IUD)
In addition to the above method of contraception, one of the following methods of contraception will ALSO be used for the duration of study participation and for 30 days following the last dose of study medication:
Diaphragm, cervical cap, or cervical shield with spermicide
Contraceptive sponge (e.g. Today Sponge)
Condom (male or female type) plus spermicide
Females of child-bearing potential must have a negative pregnancy test within the current menstrual cycle and within 7 days before starting drug
Participants must have the ability to understand, and the willingness to sign, a written informed consent document
Exclusion Criteria
Participants may not be taking medications that might interact with 9cUAB30
Participants may not be taking lipid lowering agents
Participants may not receive any other investigational agents within 30 days of enrollment nor during study participation
Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of 9cUAB30s
Participants with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Breastfeeding must be discontinued for the duration of study participation and for one month after the last dose of the study agent if the mother is treated with 9cUAB30
Individuals known to be human immunodeficiency virus (HIV)-positive may not participate in this study
Individuals with a history of cancer diagnosis or reoccurrence < 5 years from study entry may not participate; however, individuals with a history of squamous or basal cell carcinoma of the skin < 5 years from study entry will not be excluded from this study
The Schema is a timeline of the study. It indicates start/end points, visits expected, major testing to be done, and any other information that is crucial to understanding how the study was completed.
Study Schema
Visit 0: Baseline
Baseline vitals, blood tests, demographic information, and medical history gathered to determine study eligibility.
Randomization
Placebo
or
9cUAB30
20mg
40mg
80mg
160mg
240mg
Visit 1: Day 1
Participants take study treatment for the first time. Extensive urin and plasma sampling is taken to monitor 9cUAB30 levels throughout the day, used to understand how 9cUAB30 is processed after initial use. Blood tests are also taken. Treatment is halted until Visit 2.
Study Compliance Checked
Visit 2: Day 8
Participants begin taking study treatment daily, twice a day. Single urine and plasma sampling is done to check 9cUAB30 levels. Blood tests and vitals are also taken.
Study Compliance Checked
Adverse Events Reported
Visit 3: Day 15, Visit 3: Day 22, Visit 5: Day 29
Participants continue taking study treatment. Single urine and plasma sampling is done to check 9cUAB30 levels. Blood tests and vitals are also taken.
Study Compliance Checked
Adverse Events Reported
Visit 6: Day 36
Participants take study treatment for the final time. Extensive urine and plasma sampling is taken to monitor 9cUAB30 levels throughout the day. Blood tests are also taken.
Study Compliance Checked
Adverse Events Reported
Visit 7: Day 43
Single urine and plasma sampling is taken to see 9cUAB30 levels in the body after a week of non-use.
Adverse Events Reported
Results/Findings:
This phase I dose escalation study of the novel retinoid 9cUAB30 determined 160mg per day as the recommend phase 2 dose based on concentrations well over those required for RXR activation in preclinical models and tolerability. Preliminary data suggest both a favorable toxicity profile as seen in the preclinical testing in animals and our prior pilot study with oral availability and linear pharmacokinetics.
